Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio (Nasdaq: CABA) will participate in four September 2026 healthcare and investment conferences, including events hosted by Wells Fargo, Cantor, Morgan Stanley, and H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cabaletta Bio (Nasdaq: CABA) will participate in four September 2026 healthcare and investment conferences, including events hosted by Wells Fargo, Cantor, Morgan Stanley, and H.C. Wainwright. The company will hold investor meetings and several webcasted fireside chats, which will be accessible via the News and Events section of its website with replays available for 30 days.
Details
News Market Reaction – CABA
On Sep 1, the day this news came out, CABA closed 6.11% above the previous close. Argus tracked a peak move of +12.4% during that session. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner recorded 12 alerts for this stock that day. Relative volume reached 63.2x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 1 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences:
- Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.
- 2026 Cantor Global Healthcare Conference: Meetings with investors and a webcasted fireside chat at 8:35 a.m. ET on Wednesday, September 9, 2026, in New York, NY.
- Morgan Stanley 24th Annual Global Healthcare Conference: Meetings with investors and a webcasted fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.
- H.C. Wainwright 28th Annual Global Investment Conference: Meetings with investors and a fireside chat at 8:30 a.m. ET on Wednesday, September 16, 2026, in New York, NY.
The webcasted fireside chats will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Archived replays will be available for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta’s lead product candidate, rese-cel, is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology, and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts
Investors: investors@cabalettabio.com
Media: media@cabalettabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.